Tag: Iovance

Iovance Biotherapeutics is confronting a severe equity downturn, with its stock value declining by 69% since the start of the ...

Iovance Biotherapeutics finds itself navigating a complex landscape where significant regulatory achievements contrast sharply with persistent financial headwinds. The company's ...

A significant regulatory milestone in Canada has propelled Iovance Biotherapeutics' stock upward, with Health Canada granting market authorization for the ...

Iovance Biotherapeutics shares experienced a dramatic rally on Friday, closing the trading session with a substantial 13% gain at $2.49. ...

Iovance Biotherapeutics shares are confronting significant pressure from three distinct fronts as the company prepares to present at today's Wells ...

Iovance Biotherapeutics finds itself at a critical juncture as it prepares for significant investor conferences in early September. These events ...

Iovance Biotherapeutics' stock experienced significant selling pressure after the company revealed plans to raise up to $350 million through a ...

Iovance Biotherapeutics finds itself navigating a complex landscape, achieving significant medical breakthroughs with its innovative cancer therapies while simultaneously facing ...

Biopharmaceutical firm Iovance Biotherapeutics has unveiled plans to raise $350 million through an at-the-market equity offering, a move that has ...

Iovance Biotherapeutics has achieved a significant regulatory milestone with Health Canada granting market authorization for its T-cell immunotherapy, Amtagvi (lifileucel). ...